SEC Form 4 · accession 0001193125-26-262671
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gillian Cannon
Director
Period of report
Jun 5, 2026
Accepted (ET)
Jun 8, 2026 · 9:19 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | Jun 5, 2026 | S | 1,190 | $53.14 | D | 1,455 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 15, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.